Neo Modulus Completes RMB 150 Million Series A+ Financing Led by CDH VGC to Advance Regenerative Medical Solutions

VCBeat (WeChat: vcbeat) has learned that Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. (hereinafter referred to as Neo Modulus) recently announced the completion of a RMB 150 million A+ financing round. The round was led by CDH VGC (CDH Innovation and Growth Fund), with all existing institutional investors, including Huiding Investment, Suzhou SND Venture Capital, Yiling Capital, Junmao Capital, and Baofu Investment, fully following on. The proceeds will be primarily used to accelerate multiple clinical trials, establish several R&D platforms, and recruit core technical talent. Since its establishment in March 2017, Neo Modulus has cumulatively raised RMB 400 million.

Neo Modulus was co-founded by management and technical teams from China and Germany. It is an innovative enterprise dedicated to the research, development, and production of technologies that "enable human tissue repair and organ regeneration." The company operates two major R&D and production bases in China and an overseas laboratory in Freiburg, Germany. Its product portfolio encompasses multiple mainstream technological routes in the global tissue engineering field, including 3D electrospinning, conventional electrospinning, 3D bioprinting, chemical synthesis, and physical synthesis. It covers various product forms such as membranes, bone substitutes, gels, formulations, and (micro)spheres, extending to multiple clinical specialties including dentistry, ophthalmology, otorhinolaryngology, surgery, medical aesthetics, reproductive medicine, and sports medicine. Neo Modulus stands as one of China's leading comprehensive tissue engineering solution providers in the regenerative medicine sector, distinguished by its complete portfolio of clinical applications and advanced technological capabilities.

To date, Neo Modulus has developed a portfolio of over 10 implantable medical devices. Through structural designs featuring modularity and gradient layers, the company is committed to addressing complex challenges in tissue regeneration, including periodontal soft tissue augmentation and cartilage regeneration.

Neo Modulus has been selected for talent programs at various levels, including the National Foreign Experts Program, Jiangsu Provincial Innovation and Entrepreneurship Talents Program, and Gusu Leading Entrepreneurial Talents Program. It has repeatedly won awards in innovation and entrepreneurship competitions at various levels, such as the China Innovation & Entrepreneurship Competition, the "Start-up Jiangsu" Sci-Tech Entrepreneurship Competition, and the "Win in Suzhou" Youth Elite Entrepreneurship Competition, and has been listed on potential unicorn enterprise evaluation lists at various levels, including the "China Potential Unicorn Enterprise," "Sunan National Independent Innovation Demonstration Zone Potential Unicorn Enterprise," "Suzhou Unicorn Cultivation Enterprise," and "Suzhou New District Unicorn Cultivation Enterprise."

Regarding this financing round, Zhang Wencai, Co-founder, Chairman and General Manager of Neo Modulus, expressed sincere appreciation for the steadfast support and strong endorsement from CDH VGC and other investment institutions. Since its establishment, Neo Modulus has pioneered multiple core technologies in China through technology introduction and independent innovation, with several implantable medical device products rapidly progressing to the clinical trial stage. The infusion of new capital will accelerate the implementation of Neo Modulus's "Three-Multi" product architecture (multi-technology, multi-category, and multi-track) and facilitate the achievement of its "Three-High" strategic objectives: High Positioning (global team and technological deployment), High Technology (innovation driven by hard-core technologies), and High Growth (exponential expansion through multi-product integration).

Dr. Harald App, co-founder of Neo Modulus and a German full-time senior scientist, stated that the English name "Neo Modulus" signifies "innovative modulus." Moving forward, Neo Modulus will continue to uphold product innovation concepts such as modulus-based design and gradient layers, while strengthening collaborations with renowned research institutions in Germany, Austria, and other countries to develop more exceptional products.

Gao Jieliang, Partner at CDH VGC, stated that the CDH VGC healthcare team continuously monitors investment opportunities in the medical device sector, adhering to the principle of "identifying high-potential sectors through industry research, and discovering premium companies through sector research." Tissue engineering has emerged as a rapidly advancing innovative field in recent years, playing a pivotal role across multiple clinical departments. It features broad technological coverage, rapid market growth, and high technical and operational barriers. We highly value the founding team's extensive and successful industry expertise in tissue engineering. Grounded in R&D, the company has established a diversified layout spanning multiple technological pathways, products, and clinical departments, making it a rare platform-type company within the industry. As a key partner to the company, we will continue to support its ongoing development.

The CDH VGC Healthcare Team builds its core competitiveness on robust investment and research capabilities. By categorizing the healthcare sector across technological platform and indication dimensions, the team refines specific investment tracks, evaluates market trends, and has established a comprehensive and rigorous investment landscape mapping for the healthcare industry. Within the medical device sector, CDH has achieved systematic and comprehensive portfolio coverage across dental, cardiovascular, orthopedics and sports medicine, medical imaging, general surgery, neurosurgery, urology, and ophthalmology. Through granular trend analysis of specific tracks, coupled with the systematic development and comprehensive scanning of industry project pipelines, CDH strives to grasp the overarching direction of the healthcare industry while executing forward-looking investment allocations.